The approval of three spinal muscular atrophy therapies—SPINRAZA (Ionis/Biogen), EVRYSDI (Roche), and the groundbreaking gene therapy ZOLGENSMA (Novartis) has significantly advanced treatment options for a condition that previously had limited solutions. These spinal muscular atrophy (SMA) therapies offer patients more personalized care.
Nonetheless, managing SMA effectively requires more than just medications; it calls for a comprehensive, multidisciplinary approach that incorporates supportive care to reduce complications and improve the quality of life for patients and their families. This integrative model relies on coordinated efforts among neurologists, phys...
